regardless of positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from PBMs. Such organizations are typically creating obstacles to reimbursement, including steep cost criteria and prior authorization that restrict patient access. Industry indicate that